Guy T. Carter
Guy T. Carter has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Haiyin He
Biosortia Pharmaceuticals Hollings Marine Laboratory, Charleston, South Carolina 29412, United States
3 shared publications- Matthew J. Bertin
Case Western Reserve University
3 shared publications Paul G. Wahome
Biosortia Pharmaceuticals Hollings Marine Laboratory, Charleston, South Carolina 29412, United States
3 shared publicationsShiBiao Wu
Biosortia Pharmaceuticals Hollings Marine Laboratory, Charleston, South Carolina 29412, United States
3 shared publicationsKevin R. Beauchesne
Biosortia Pharmaceuticals , Hollings Marine Laboratory , 331 Ft. Johnson Road , Charleston , South Carolina 29412 , United States
2 shared publicationsPeter D. R. Moeller
National Oceanic and Atmospheric Administration , Hollings Marine Laboratory , 331 Ft. Johnson Road , Charleston , South Carolina 29412 , United States
2 shared publications
Latest Publications
- Open Access
- 4 June 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (23) , 15472-15478
New Micropeptins with Anti-Neuroinflammatory Activity Isolated from a Cyanobacterial Bloom
- 4 June 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (23) , 15472-15478
Open AccessNew Micropeptins with Anti-Neuroinflammatory Activity Isolated from a Cyanobacterial Bloom
- Open Access
- 28 October 2018
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 81 (11) , 2576-2581
Cyanobufalins: Cardioactive Toxins from Cyanobacterial Blooms
Cyanobufalins A–C (1–3), a new series of cardiotoxic steroids, have been discovered from cyanobacterial blooms in Buckeye Lake and Grand Lake St. Marys in Ohio. Compounds 1–3 contain distinctive structural features, including geminal methyl groups at C-4, a 7,8 double bond, and a C-16 chlorine substituent that distinguish them from plant- or animal-derived congeners. Despite these structural differences, the compounds are qualitatively identical to bufalin in their cytotoxic profiles versus cell lines in tissue culture and cardiac activity, as demonstrated in an impedance-based cellular assay conducted with IPSC-derived cardiomyocytes. Cyanobufalins are nonselectively toxic to human cells in the single-digit nanomolar range and show stimulation of contractility in cardiomyocytes at sub-nanomolar concentrations. The estimated combined concentration of 1–3 in the environment is in the same nanomolar range, and consequently more precise quantitative analyses are recommended along with more detailed cardiotoxicity studies. This is the first time that cardioactive steroid toxins have been found associated with microorganisms in an aquatic environment. Several factors point to a microbial biosynthetic origin for the cyanobufalins.
- 28 October 2018
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 81 (11) , 2576-2581
Open AccessCyanobufalins: Cardioactive Toxins from Cyanobacterial Blooms
Cyanobufalins A–C (1–3), a new series of cardiotoxic steroids, have been discovered from cyanobacterial blooms in Buckeye Lake and Grand Lake St. Marys in Ohio. Compounds 1–3 contain distinctive structural features, including geminal methyl groups at C-4, a 7,8 double bond, and a C-16 chlorine substituent that distinguish them from plant- or animal-derived congeners. Despite these structural differences, the compounds are qualitatively identical to bufalin in their cytotoxic profiles versus cell lines in tissue culture and cardiac activity, as demonstrated in an impedance-based cellular assay conducted with IPSC-derived cardiomyocytes. Cyanobufalins are nonselectively toxic to human cells in the single-digit nanomolar range and show stimulation of contractility in cardiomyocytes at sub-nanomolar concentrations. The estimated combined concentration of 1–3 in the environment is in the same nanomolar range, and consequently more precise quantitative analyses are recommended along with more detailed cardiotoxicity studies. This is the first time that cardioactive steroid toxins have been found associated with microorganisms in an aquatic environment. Several factors point to a microbial biosynthetic origin for the cyanobufalins.
- 30 May 2018
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 81 (6) , 1368-1375
Microcystins Containing Doubly Homologated Tyrosine Residues from a Microcystis aeruginosa Bloom: Structures and Cytotoxicity
Four new microcystin congeners are described including the first three examples of microcystins containing the rare doubly homologated tyrosine residue 2-amino-5-(4-hydroxyphenyl)pentanoic acid (Ahppa) (1–4). Large-scale harvesting and biomass processing allowed the isolation of substantial quantities of these compounds, thus enabling complete structure determination by NMR as well as cytotoxicity evaluation against selected cancer cell lines. The new Ahppa-toxins all incorporate Ahppa residues at the 2-position, and one of these also has a second Ahppa at position 4. The two most lipophilic Ahppa-containing microcystins showed 10-fold greater cytotoxic potency against human tumor cell lines (A549 and HCT-116) compared to microcystin-LR (5). The presence of an Ahppa residue in microcystin congeners is difficult to ascertain by MS methods alone, due to the lack of characteristic fragment ions derived from the doubly homologated side chain. Owing to their unexpected cytotoxic potency, the potential impact of the compounds on human health should be further evaluated.
- 30 May 2018
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 81 (6) , 1368-1375
Microcystins Containing Doubly Homologated Tyrosine Residues from a Microcystis aeruginosa Bloom: Structures and Cytotoxicity
Four new microcystin congeners are described including the first three examples of microcystins containing the rare doubly homologated tyrosine residue 2-amino-5-(4-hydroxyphenyl)pentanoic acid (Ahppa) (1–4). Large-scale harvesting and biomass processing allowed the isolation of substantial quantities of these compounds, thus enabling complete structure determination by NMR as well as cytotoxicity evaluation against selected cancer cell lines. The new Ahppa-toxins all incorporate Ahppa residues at the 2-position, and one of these also has a second Ahppa at position 4. The two most lipophilic Ahppa-containing microcystins showed 10-fold greater cytotoxic potency against human tumor cell lines (A549 and HCT-116) compared to microcystin-LR (5). The presence of an Ahppa residue in microcystin congeners is difficult to ascertain by MS methods alone, due to the lack of characteristic fragment ions derived from the doubly homologated side chain. Owing to their unexpected cytotoxic potency, the potential impact of the compounds on human health should be further evaluated.
- 3 July 2017
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 34 (7) , 685-686
Editorial: Are natural products the solution to antimicrobial resistance?
A graphical abstract is available for this content
- 3 July 2017
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 34 (7) , 685-686
Editorial: Are natural products the solution to antimicrobial resistance?
A graphical abstract is available for this content
- 27 January 2014
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 31 (6) , 711-717
NP/MS since 1970: from the basement to the bench top
This Highlight explores the evolution of applications of mass spectrometric technologies in the context of natural products research since the 1970's. The central themes are the analysis of mixtures, dereplication (identification) and structure determination. The ascension of HPLC as the method of choice for the analysis of pharmaceuticals was a driving force for the development of interfaces for coupling of HPLC and MS. An example of sequential analysis of fragment ions or MS/MS or MSn methods to provide detailed structural information on muraymycins, a family of uridyl-peptide antibiotics, is presented.
- 27 January 2014
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 31 (6) , 711-717
NP/MS since 1970: from the basement to the bench top
This Highlight explores the evolution of applications of mass spectrometric technologies in the context of natural products research since the 1970's. The central themes are the analysis of mixtures, dereplication (identification) and structure determination. The ascension of HPLC as the method of choice for the analysis of pharmaceuticals was a driving force for the development of interfaces for coupling of HPLC and MS. An example of sequential analysis of fragment ions or MS/MS or MSn methods to provide detailed structural information on muraymycins, a family of uridyl-peptide antibiotics, is presented.
- 4 October 2013
- Published by Springer Nature
- p. 177-191
Uridyl Peptide Antibiotics: Developments in Biosynthesis and Medicinal Chemistry
- 4 October 2013
- Published by Springer Nature
- p. 177-191
Uridyl Peptide Antibiotics: Developments in Biosynthesis and Medicinal Chemistry
- 1 November 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 19 (22) , 6556
Harnessing the biosynthetic capacity of marine-derived organisms
- 1 November 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 19 (22) , 6556
Harnessing the biosynthetic capacity of marine-derived organisms
- 12 September 2011
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 28 (11) , 1783-1789
Natural products and Pharma 2011: Strategic changes spur new opportunities
Although natural products have been marginalized by major pharmaceutical companies over the last 20–30 years, the changing landscape of drug discovery now favors a greatly enhanced role for Nature's privileged structures. Screening for drug leads in phenotypic screens provides the best opportunity to realize the value of natural products. Advances in total synthesis, especially function-oriented syntheses and biosynthetic technologies offer new avenues for the medicinal chemical optimization of biologically active secondary metabolites. Genomic research has given new insights into biosynthetic processes as well as providing evidence that a wealth of unrealized biosynthetic potential remains to be explored. As Pharma strives to develop innovative and highly effective new drugs, natural products will be increasingly valued as sources of novel leads whose further development will be expedited by emerging technologies.
- 12 September 2011
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 28 (11) , 1783-1789
Natural products and Pharma 2011: Strategic changes spur new opportunities
Although natural products have been marginalized by major pharmaceutical companies over the last 20–30 years, the changing landscape of drug discovery now favors a greatly enhanced role for Nature's privileged structures. Screening for drug leads in phenotypic screens provides the best opportunity to realize the value of natural products. Advances in total synthesis, especially function-oriented syntheses and biosynthetic technologies offer new avenues for the medicinal chemical optimization of biologically active secondary metabolites. Genomic research has given new insights into biosynthetic processes as well as providing evidence that a wealth of unrealized biosynthetic potential remains to be explored. As Pharma strives to develop innovative and highly effective new drugs, natural products will be increasingly valued as sources of novel leads whose further development will be expedited by emerging technologies.